Pharmaceuticals APAC News & Press Release Distribution

Pharmaceuticals

All
Global

Frost & Sullivan co-published Recombinant Type III Triple-Helix Collagen Whitepaper with Everon Healthcare

SHANGHAI, Oct. 1, 2024 /PRNewswire/ -- Frost & Sullivan and Everon Healthcare have conducted extensive investigation across the recombinant collagen Industry and co-published the "Recombinant Type III Triple-Helix Collagen Whitepaper" on Sep. 29th, 2024, which aims to analyze the latest research a...

2024-10-01 17:28 1837

TraceLink Releases Amadeus, the First Generative AI Assistant for Accelerating the Digitalization of Supply Networks on the Opus Platform

Trained on a rich set of information from a unified content repository, Opus Orchestration Architects, Solution Designers, Network Administrators, and those simply interested in learning more about TraceLink's solutions are empowered with information in seconds BOSTON, Oct. 1, 2024 /PRNewswire/ ...

2024-10-01 16:00 1368

Great Place To Work® Australia and New Zealand names 15 Best Workplaces in Healthcare, Biopharma & Social Assistance in 2024

SYDNEY, Oct. 1, 2024 /PRNewswire/ -- Great Place To Work® ANZ, the global authority on workplace culture today announces theirinaugural 15 Best Workplaces™ in Healthcare, Social Assistance and BioPharma in 2024. The companies are announced across two lists: Best Workplaces in Biotechnology a...

2024-10-01 07:00 8040

Alphamab Oncology and CSPC Achieved a Licensing Agreement on Anti-HER2 Bispecific ADC JSKN003 in Mainland China

SUZHOU, China, Sept. 30, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966 HK) announced that Jiangsu Alphamab Biopharmaceuticals Co., Ltd. ("Alphamab"), a wholly-owned subsidiary of Alphamab Oncology ("the Company"), entered into a licensing agreement (the "Licensing Agreement") on anti-H...

2024-09-30 10:35 3234

Multiple Study Results of Kelun-Biotech's TROP2-ADC SKB264 (sac-TMT) at 2024 CSCO Congress

CHENGDU, China, Sept. 29, 2024 /PRNewswire/ -- From September 25th to 29th, the 27th China Clinical Oncology Congress and the 2024 CSCO Annual Meeting were held inXiamen. Experts and scholars in the field of oncology from all over China gathered together to discuss the hotspots at the forefront o...

2024-09-29 11:52 2546

Multiple Study Results of Kelun-Biotech's TROP2-ADC SKB264 (sac-TMT) at 2024 CSCO Congress

Frost & Sullivan Released Report: "2024 Blue Book on Chinese Biopharmaceuticals Going Global: Current Status and Trends"

SHANGHAI, Sept. 28, 2024 /PRNewswire/ -- Frost & Sullivan released the "2024 Blue Book on Chinese Biopharmaceuticals Going Global: Current Status and Trends" which focus on the progress of Chinese biopharmaceuticals going global and analyzes the driving forces behind their accelerated global expa...

2024-09-28 09:11 3251

LakeShore Biopharma Announces Results of Extraordinary General Meeting on Share Consolidation

GAITHERSBURG, Md., Sept. 27, 2024 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for ...

2024-09-27 19:00 1489

Anbogen Announces Drug Supply Collaboration with BeiGene to Evaluate Combination Therapy in Colorectal Cancer

TAIPEI, Sept. 27, 2024 /PRNewswire/ -- Anbogen, a clinical-stage biotech company, today announced a drug supply collaboration to evaluate the combination of Anbogen's HDAC inhibitor, ABT-301, with BeiGene's anti-PD-1 antibody tislelizumab, in patients with mismatch repair–proficient (pMMR) or mi...

2024-09-27 16:00 1547

ArkBio Announces Publication of Phase 3 Clinical Trial Results of Ziresovir for the Treatment of RSV Infection in The New England Journal of Medicine

SHANGHAI, Sept. 26, 2024 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio"), a clinical stage biopharmaceutical company focused on the development of therapeutics in respiratory, infectious and pediatric diseases, announced that the results of the phase 3 clinical trial of zireso...

2024-09-26 20:28 1828

Innovent Announces NMPA Acceptance of NDA for Picankibart (Anti-IL-23p19 Antibody) for Treating Moderate to Severe Plaque Psoriasis

SAN FRANCISCO and SUZHOU, China, Sept. 26, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metaboli...

2024-09-26 12:15 1857

Rx-360 Announces Approval as a Pilot Center of Excellence for the APEC Regulatory Harmonization Steering Committee

PHILADELPHIA, Sept. 25, 2024 /PRNewswire/ -- Rx-360® is pleased to announce that it has been accepted as a Pilot Center of Excellence (CoE) for the APEC Regulatory Harmonization Steering Committee. The pilot will be focused on the Global Medical Product Supply Chain Integrity Priority Work Area R...

2024-09-25 21:09 1552

GSK's Arexvy is a vaccine approved to protect older adults from respiratory syncytial virus (RSV) disease in Malaysia

* Adults aged 60 and over with underlying co-morbidities are at high risk of developing severe infections from RSV * Vaccine showed 82.6% overall vaccine efficacy against RSV-LRTD with 94.6% efficacy observed in adults with co-morbidities vii KUALA LUMPUR, Malaysia, Sept. 25, 2024 /PRNewswire...

2024-09-25 16:45 1624

GSK's Arexvy is a vaccine approved to protect older adults from respiratory syncytial virus (RSV) disease in Malaysia

Belief BioMed to Collaborate with AskBio to Explore the Potential of New Gene Therapies

* Belief BioMed and AskBio will work together to advance potential gene therapies in diseases with high unmet medical need, using a liver-targeted approach. SHANGHAI, Sept. 25, 2024 /PRNewswire/ -- Belief BioMed Inc. (BBM), a biotech company focusing on innovative gene therapies, today announce...

2024-09-25 14:58 1450

Biocon Biologics Announces New Dermatology Data to Be Presented at EADV Congress 2024

* Switching between adalimumab and adalimumab-fkjp in Phase 3 study in patients with chronic plaque psoriasis supports interchangeability between adalimumab and adalimumab-fkjp * Biosimilarity between Bmab 1200 and reference biologic-Ustekinumab in pivotal Phase 3 trial in patients with moder...

2024-09-25 13:21 1279

Veltassa® (patiromer) approved in Japan for the treatment of adults with hyperkalemia

Veltassa® offers effective and well-tolerated long-term potassium control in chronic kidney disease and chronic heart failure patients1-5 Zeria Pharmaceutical Co., Ltd. to market Veltassa® in Japan ST. GALLEN, Switzerland, Sept. 24, 2024 /PRNewswire/ -- CSL Vifor today announced thatJapan's Mini...

2024-09-24 15:30 3022

Antengene Announces XPOVIO® (selinexor) Approved for Commercialization in Thailand

* XPOVIO® is the first and only approved XPO1 inhibitor in Thailand. * XPOVIO® has been approved for multiple indications in nine markets across the APAC region. Antengene has submitted a new drug application (NDA) for XPOVIO ® in Indonesia with approval expected in the second half of 2024. ...

2024-09-23 17:42 3440

Nuance Pharma Announces Expansion of Bentrio License and Distribution Agreement with Altamira Therapeutics in East and South East Asia

* Nuance Pharma successfully launched Bentrio® nasal spray for protection against airborne particles inHong Kong and filed request for marketing authorization for Mainland China * Extension of Exclusive License and Distribution Agreement to include seven additional countries across East andS...

2024-09-23 15:00 1611

Telix to Acquire RLS to Expand North American Manufacturing and Distribution Platform

MELBOURNE, Australia, INDIANAPOLIS and LAKE MARY, Fla., Sept. 23, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) and RLS (USA) Inc. (RLS, RLS Radiopharmacies), America's only Joint Commission-accredited radiopharmacy network distributing PET[1], SPECT[2] and th...

2024-09-23 07:38 1610

Henlius Receives Positive CHMP Opinion for HANSIZHUANG as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer

* HANSIZHUANG (serplulimab) is the world's first anti-PD-1 mAb for first-line treatment of ES- SCLC - * HANSIZHUANG (serplulimab) is expected to become the first and only anti-PD-1 monoclonal antibody available inEurope for first-line treatment of ES- SCLC - * HANSIZHUANG (serplulimab) ha...

2024-09-21 13:42 4248

Cambrex Announces New Liquid-Phase Peptide Synthesis Manufacturing Technology

EAST RUTHERFORD, N.J., Sept. 19, 2024 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO), today announced that Snapdragon Chemistry, a Cambrex company, has successfully developed a new liquid-phase peptide synthesis (LPPS) technology that utilizes...

2024-09-19 18:00 1553

1 ... 3 4 567 8 9 ... 187

Week's Top Stories

Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies

[Picked up by 283 media titles]

2024-11-20 09:00